<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193127</url>
  </required_header>
  <id_info>
    <org_study_id>C09-001</org_study_id>
    <nct_id>NCT01193127</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeros Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of OMS302 (the study drug) in
      individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and
      effective at maintaining an adequately dilated pupil during surgery and reducing
      post-operative symptoms of discomfort (such as eye pain and irritation).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pupil Diameter (mm) During Surgery</measure>
    <time_frame>During surgery (immediately prior to surgical incision to wound closure)</time_frame>
    <description>Pupil diameter from surgical baseline (immediately prior to surgical incision) to the end of the surgical procedure (wound closure) was summarized using descriptive statistics by treatment group and time point. Repeated measures analyses of variance were used to test for differences in the maintenance of mydriasis. The repeated measures model included change from baseline pupil diameter as the response variable and treatment (OMS302, ketorolac tromethamine, and vehicle), time point (as a categorical variable) and the stratification factor lens opacities classification system II (LOCS II) grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working-correlation structure was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Pain Visual Analog Scale (VAS) Score (mm) Within 12 Hours Postoperatively</measure>
    <time_frame>through 12 hours post-surgery</time_frame>
    <description>For the primary analysis of this endpoint, only the results on the day of operation at 2, 4, 6, 8 and 10-12 hours were utilized. The VAS scores (where 0 = no pain and 100 = worst possible pain) were summarized by treatment group and time point. Repeated measures analyses of variance were used to test for differences in postoperative ocular pain. The repeated measures model included VAS pain score as the response variable and treatment (OMS302, phenylephrine hydrochloride (PE), and vehicle), time point (as a categorical variable) and the stratification factor LOCS II grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working correlation structure was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, Six Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, Seven Days Post-Surgery</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Tearing, 30 Days Post-Surgery/ Early Termination</measure>
    <time_frame>up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia Six Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia Seven Days Post-Surgery</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Photophobia 30 Days Post-Surgery /Early Termination</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge 2 Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge Six Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge Seven Days Post-Surgery</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Eye Discharge 30 Days Post-Surgery/Early Termination</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching 6 Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching Seven Days Post-Surgery</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Itching 30 Days Post-Surgery/Early Termination</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation Six Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation Seven Days Post-Surgery 7 Days</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Foreign Body Sensation 30 Days Post-Surgery/Early Termination</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness Six Hours Post-Surgery</measure>
    <time_frame>Six hours</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness One Day Post-Surgery</measure>
    <time_frame>One day</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness Two Days Post-Surgery</measure>
    <time_frame>Two days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness Seven Days Post-Surgery</measure>
    <time_frame>Seven days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness 14 Days Post-Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Symptoms Using Numerical Rating System - Haziness 30 Days Post-Surgery/Early Termination</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System - NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Day 1</measure>
    <time_frame>One day</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Day 2</measure>
    <time_frame>Two days</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Day 7</measure>
    <time_frame>Seven days</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BVCA) - Log Score, Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, 2 Hours Post Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>TPostoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 1</measure>
    <time_frame>One day</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 2</measure>
    <time_frame>Two days</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 7</measure>
    <time_frame>Seven days</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Two Hours Post-surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 1</measure>
    <time_frame>One day</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 2</measure>
    <time_frame>Two days</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 7</measure>
    <time_frame>Seven days</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Two Hours Post-Surgery</measure>
    <time_frame>Two hours</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Day 1</measure>
    <time_frame>One day</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Day 2</measure>
    <time_frame>Two days</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Day 7</measure>
    <time_frame>Seven days</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Anterior Chamber Cell Count, Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Pain VAS Score After Day 0</measure>
    <time_frame>43 days</time_frame>
    <description>VAS pain scores (where 0 = no pain and 100 = worst possible pain) after the day of surgery were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Use of Ophthalmic Anti-inflammatory Medications</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Ophthalmic anti-inflammatory medications were identified by reviewing concomitant medications. Subject incidence of ophthalmic anti-inflammatory medication use by post-surgery day was presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Pain Medications at Day 1</measure>
    <time_frame>One day</time_frame>
    <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Pain Medications After Day 1</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>OMS302 Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OMS302 Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS302 Mydriatic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OMS302 Mydriatic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS302 Anti-inflammatory Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OMS302 Anti-inflammatory Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced Salt Solution (BSS) Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Balanced Salt Solution (BSS) Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMS302 Solution</intervention_name>
    <arm_group_label>OMS302 Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMS302 Mydriatic Solution</intervention_name>
    <arm_group_label>OMS302 Mydriatic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMS302 Anti-inflammatory Solution</intervention_name>
    <arm_group_label>OMS302 Anti-inflammatory Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced Salt Solution (BSS) Solution</intervention_name>
    <arm_group_label>Balanced Salt Solution (BSS) Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent and willing to voluntarily provide informed consent

          -  18 years of age or older

          -  In good general health needing to undergo cataract extraction with lens replacement
             surgery in one eye, under topical anesthesia

          -  Other inclusion criteria to be evaluated by the investigator

        Exclusion Criteria:

          -  No allergies to the medications and/or the active ingredients of any of the study
             medications

          -  No medications with the same activities as the of the active ingredients in OMS302 for
             defined time intervals prior to and after surgery

          -  No other significant eye injuries, eye conditions or general medical conditions likely
             to interfere with the evaluation of the study medication

          -  Other exclusion criteria to be evaluated by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Ft. Myers</city>
        <state>Florida</state>
        <zip>33903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gretna</city>
        <state>Louisiana</state>
        <zip>70056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>July 2, 2014</results_first_submitted>
  <results_first_submitted_qc>August 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <disposition_first_submitted>October 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2012</disposition_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Mydriatics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Balanced Salt Solution (BSS)</title>
          <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
        </group>
        <group group_id="P2">
          <title>OMS302 Mydriatic Solution (PE)</title>
          <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
        </group>
        <group group_id="P3">
          <title>OMS302 Anti-inflammatory Solution (KE)</title>
          <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
        </group>
        <group group_id="P4">
          <title>OMS302 Solution</title>
          <description>OMS302 Solution
OMS302 Solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Surgery Cancelled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treated</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Balanced Salt Solution (BSS)</title>
          <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
        </group>
        <group group_id="B2">
          <title>OMS302 Mydriatic Solution (PE)</title>
          <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
        </group>
        <group group_id="B3">
          <title>OMS302 Anti-inflammatory Solution (KE)</title>
          <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
        </group>
        <group group_id="B4">
          <title>OMS302 Solution</title>
          <description>OMS302 Solution
OMS302 Solution</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="9.6"/>
                    <measurement group_id="B2" value="67.6" spread="10.6"/>
                    <measurement group_id="B3" value="66.8" spread="8.6"/>
                    <measurement group_id="B4" value="66.4" spread="11.2"/>
                    <measurement group_id="B5" value="67.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pupil Diameter (mm) During Surgery</title>
        <description>Pupil diameter from surgical baseline (immediately prior to surgical incision) to the end of the surgical procedure (wound closure) was summarized using descriptive statistics by treatment group and time point. Repeated measures analyses of variance were used to test for differences in the maintenance of mydriasis. The repeated measures model included change from baseline pupil diameter as the response variable and treatment (OMS302, ketorolac tromethamine, and vehicle), time point (as a categorical variable) and the stratification factor lens opacities classification system II (LOCS II) grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working-correlation structure was used.</description>
        <time_frame>During surgery (immediately prior to surgical incision to wound closure)</time_frame>
        <population>Subjects with interpretable video recordings obtained during surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Pupil Diameter (mm) During Surgery</title>
          <description>Pupil diameter from surgical baseline (immediately prior to surgical incision) to the end of the surgical procedure (wound closure) was summarized using descriptive statistics by treatment group and time point. Repeated measures analyses of variance were used to test for differences in the maintenance of mydriasis. The repeated measures model included change from baseline pupil diameter as the response variable and treatment (OMS302, ketorolac tromethamine, and vehicle), time point (as a categorical variable) and the stratification factor lens opacities classification system II (LOCS II) grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working-correlation structure was used.</description>
          <population>Subjects with interpretable video recordings obtained during surgery.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n = 53, 49, 52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.0"/>
                    <measurement group_id="O2" value="8.0" spread="1.8"/>
                    <measurement group_id="O3" value="8.1" spread="1.6"/>
                    <measurement group_id="O4" value="9.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute; n = 53, 48, 52, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.1"/>
                    <measurement group_id="O2" value="8.3" spread="1.9"/>
                    <measurement group_id="O3" value="8.3" spread="1.6"/>
                    <measurement group_id="O4" value="9.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes; n = 53, 49, 52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.0"/>
                    <measurement group_id="O2" value="8.3" spread="1.7"/>
                    <measurement group_id="O3" value="8.2" spread="1.8"/>
                    <measurement group_id="O4" value="9.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minutes; n = 53, 49, 52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.2"/>
                    <measurement group_id="O2" value="8.4" spread="1.8"/>
                    <measurement group_id="O3" value="8.1" spread="1.7"/>
                    <measurement group_id="O4" value="9.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 minutes; n = 52, 49, 52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="2.0"/>
                    <measurement group_id="O2" value="8.4" spread="1.8"/>
                    <measurement group_id="O3" value="7.9" spread="1.8"/>
                    <measurement group_id="O4" value="9.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes; n = 52, 49, 51, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.3"/>
                    <measurement group_id="O2" value="8.2" spread="1.9"/>
                    <measurement group_id="O3" value="7.9" spread="1.9"/>
                    <measurement group_id="O4" value="9.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 minutes; n = 51, 45, 50, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.6"/>
                    <measurement group_id="O2" value="8.1" spread="2.0"/>
                    <measurement group_id="O3" value="7.7" spread="1.8"/>
                    <measurement group_id="O4" value="9.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes; n = 45, 37, 44, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.7"/>
                    <measurement group_id="O2" value="8.0" spread="2.3"/>
                    <measurement group_id="O3" value="7.2" spread="2.0"/>
                    <measurement group_id="O4" value="9.0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 minutes; n = 34, 28, 40, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.7"/>
                    <measurement group_id="O2" value="7.8" spread="2.5"/>
                    <measurement group_id="O3" value="7.1" spread="2.1"/>
                    <measurement group_id="O4" value="8.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 minutes; n = 27, 25, 32, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="3.0"/>
                    <measurement group_id="O2" value="8.1" spread="2.6"/>
                    <measurement group_id="O3" value="7.0" spread="1.9"/>
                    <measurement group_id="O4" value="8.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes; n = 26, 19, 25, 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.5"/>
                    <measurement group_id="O2" value="8.3" spread="2.8"/>
                    <measurement group_id="O3" value="7.0" spread="1.5"/>
                    <measurement group_id="O4" value="8.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 minutes; n = 24, 18, 22, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="2.9"/>
                    <measurement group_id="O2" value="8.3" spread="2.7"/>
                    <measurement group_id="O3" value="7.1" spread="1.4"/>
                    <measurement group_id="O4" value="8.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 minutes; n = 22, 17, 20, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="3.0"/>
                    <measurement group_id="O2" value="8.0" spread="2.7"/>
                    <measurement group_id="O3" value="7.0" spread="1.1"/>
                    <measurement group_id="O4" value="9.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 minutes; n = 14, 13, 16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.6"/>
                    <measurement group_id="O2" value="8.0" spread="2.9"/>
                    <measurement group_id="O3" value="6.8" spread="1.4"/>
                    <measurement group_id="O4" value="8.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 minutes; n = 10, 8, 13, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.8"/>
                    <measurement group_id="O2" value="7.7" spread="2.8"/>
                    <measurement group_id="O3" value="6.5" spread="1.4"/>
                    <measurement group_id="O4" value="9.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes; n = 8, 7, 8, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.6"/>
                    <measurement group_id="O2" value="7.9" spread="2.7"/>
                    <measurement group_id="O3" value="6.9" spread="2.1"/>
                    <measurement group_id="O4" value="9.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 minutes; n = 7, 6, 7, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.9"/>
                    <measurement group_id="O2" value="8.4" spread="3.0"/>
                    <measurement group_id="O3" value="6.7" spread="1.6"/>
                    <measurement group_id="O4" value="10.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 minutes; n = 7, 5, 6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.8"/>
                    <measurement group_id="O2" value="7.2" spread="1.4"/>
                    <measurement group_id="O3" value="6.8" spread="1.7"/>
                    <measurement group_id="O4" value="12.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 minutes; n = 6, 3, 5, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.6"/>
                    <measurement group_id="O2" value="7.9" spread="0.9"/>
                    <measurement group_id="O3" value="6.8" spread="3.1"/>
                    <measurement group_id="O4" value="12.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19 minutes; n = 3, 3, 4, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.1"/>
                    <measurement group_id="O2" value="7.8" spread="1.0"/>
                    <measurement group_id="O3" value="6.7" spread="3.9"/>
                    <measurement group_id="O4" value="11.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes; n = 2, 2, 2, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.2"/>
                    <measurement group_id="O2" value="8.1" spread="1.4"/>
                    <measurement group_id="O3" value="5.2" spread="0.9"/>
                    <measurement group_id="O4" value="12.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 minutes; n = 2, 2, 0, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.3"/>
                    <measurement group_id="O2" value="8.0" spread="1.5"/>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="12.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>22 minutes; n = 1, 2, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0"/>
                    <measurement group_id="O2" value="7.5" spread="1.5"/>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="14.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 minutes; n = 1, 1, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0"/>
                    <measurement group_id="O2" value="6.6" spread="0"/>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="14.6" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 minutes; n = 1, 1, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0"/>
                    <measurement group_id="O2" value="7.1" spread="0"/>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="13.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 minutes; n = 1, 1, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0"/>
                    <measurement group_id="O2" value="6.4" spread="0"/>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="13.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26 minutes; n = 1, 0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="17.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 minutes; n = 1, 0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="17.4" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 minutes; n = 1, 0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="17.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>29 minutes; n = 1, 0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="18.7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes; n = 1, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 minutes; n = 1, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0"/>
                    <measurement group_id="O2" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O3" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                    <measurement group_id="O4" value="NA">No subjects in this treatment group continuing surgery past this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>Repeated measures model includes treatment (OMS302, ketorolac tromethamine, and vehicle), time-point and LOCS II grade as covariates</p_value_desc>
            <method>repeated measures model</method>
            <method_desc>All data time points collected used in the analysis.</method_desc>
            <param_type>least-squares mean difference</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>OMS302 - Vehicle (BSS)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>Repeated measures model includes treatment (OMS302, ketorolac tromethamine, and vehicle), time-point and LOCS II grade as covariates.</p_value_desc>
            <method>repeated measures model</method>
            <method_desc>OMS302 - ketorolac tromethamine</method_desc>
            <param_type>least-squares mean difference</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Pain Visual Analog Scale (VAS) Score (mm) Within 12 Hours Postoperatively</title>
        <description>For the primary analysis of this endpoint, only the results on the day of operation at 2, 4, 6, 8 and 10-12 hours were utilized. The VAS scores (where 0 = no pain and 100 = worst possible pain) were summarized by treatment group and time point. Repeated measures analyses of variance were used to test for differences in postoperative ocular pain. The repeated measures model included VAS pain score as the response variable and treatment (OMS302, phenylephrine hydrochloride (PE), and vehicle), time point (as a categorical variable) and the stratification factor LOCS II grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working correlation structure was used.</description>
        <time_frame>through 12 hours post-surgery</time_frame>
        <population>Subjects with postoperative VAS scores.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Pain Visual Analog Scale (VAS) Score (mm) Within 12 Hours Postoperatively</title>
          <description>For the primary analysis of this endpoint, only the results on the day of operation at 2, 4, 6, 8 and 10-12 hours were utilized. The VAS scores (where 0 = no pain and 100 = worst possible pain) were summarized by treatment group and time point. Repeated measures analyses of variance were used to test for differences in postoperative ocular pain. The repeated measures model included VAS pain score as the response variable and treatment (OMS302, phenylephrine hydrochloride (PE), and vehicle), time point (as a categorical variable) and the stratification factor LOCS II grade as predictor variables. A generalized estimating equation (GEE) approach with an AR(1) working correlation structure was used.</description>
          <population>Subjects with postoperative VAS scores.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="14.7"/>
                    <measurement group_id="O2" value="9.4" spread="16.8"/>
                    <measurement group_id="O3" value="4.1" spread="12.7"/>
                    <measurement group_id="O4" value="5.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="19.3"/>
                    <measurement group_id="O2" value="10.5" spread="16.9"/>
                    <measurement group_id="O3" value="4.8" spread="12.3"/>
                    <measurement group_id="O4" value="5.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="17.2"/>
                    <measurement group_id="O2" value="9.5" spread="14.9"/>
                    <measurement group_id="O3" value="4.3" spread="10.9"/>
                    <measurement group_id="O4" value="3.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="14.7"/>
                    <measurement group_id="O2" value="12.2" spread="16.9"/>
                    <measurement group_id="O3" value="4.0" spread="11.0"/>
                    <measurement group_id="O4" value="4.0" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-12 hours post-surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="18.3"/>
                    <measurement group_id="O2" value="11.8" spread="17.1"/>
                    <measurement group_id="O3" value="3.4" spread="9.2"/>
                    <measurement group_id="O4" value="4.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0421</p_value>
            <p_value_desc>Repeated measures model includes treatment (OMS302, PE and vehicle), time point and LOCS II grade as covariates</p_value_desc>
            <method>repeated measures model</method>
            <param_type>least-squares mean difference</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>OMS302 - Vehicle (BSS)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <p_value_desc>Repeated measures model includes treatment (OMS302, PE and vehicle), time point and LOCS II grade as covariates.</p_value_desc>
            <method>repeated measures model</method>
            <param_type>least-squares mean difference</param_type>
            <param_value>-5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
            <estimate_desc>OMS302 - PE</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, Two Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, Two Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.630</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, Six Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, Six Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.051</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.480</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.439</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, Seven Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, Seven Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.480</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.742</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Tearing, 30 Days Post-Surgery/ Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Tearing, 30 Days Post-Surgery/ Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.606</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel-Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia Two Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia Two Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.893</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.553</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.412</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia Six Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia Six Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.519</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia Seven Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia Seven Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.525</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.442</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Photophobia 30 Days Post-Surgery /Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Photophobia 30 Days Post-Surgery /Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.695</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 2 Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 2 Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.298</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Six Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Six Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.589</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.478</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.521</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.432</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Seven Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge Seven Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.156</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.381</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.646</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.950</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 30 Days Post-Surgery/Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Eye Discharge 30 Days Post-Surgery/Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching Two Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching Two Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.789</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.977</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching 6 Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching 6 Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.632</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.778</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.528</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.353</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching Seven Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching Seven Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.596</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.811</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.552</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.549</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Itching 30 Days Post-Surgery/Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Itching 30 Days Post-Surgery/Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Two Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Two Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.681</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.429</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Six Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS) Solution</title>
            <description>Balanced Salt Solution (BSS) Solution
Balanced Salt Solution (BSS) Solution</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Six Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS) Solution</title>
            <description>Balanced Salt Solution (BSS) Solution
Balanced Salt Solution (BSS) Solution</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.244</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.790</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Seven Days Post-Surgery 7 Days</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation Seven Days Post-Surgery 7 Days</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.228</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.755</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.298</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation 30 Days Post-Surgery/Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Foreign Body Sensation 30 Days Post-Surgery/Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness Two Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness Two Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.320</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.390</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness Six Hours Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Six hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness Six Hours Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.778</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.477</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness One Day Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness One Day Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.374</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness Two Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness Two Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness Seven Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness Seven Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness 14 Days Post-Surgery</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness 14 Days Post-Surgery</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Symptoms Using Numerical Rating System  Haziness 30 Days Post-Surgery/Early Termination</title>
        <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptoms Using Numerical Rating System  Haziness 30 Days Post-Surgery/Early Termination</title>
          <description>The ocular symptom outcomes were based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System  NRS) at each time point for each assessment (tearing, photophobia, eye discharge, itching, foreign body sensation, and haziness). Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Baseline</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>Baseline</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Baseline</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.2"/>
                    <measurement group_id="O3" value="0.4" spread="0.2"/>
                    <measurement group_id="O4" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.921</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wicoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 1</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 1</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                    <measurement group_id="O4" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.701</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 2</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 2</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                    <measurement group_id="O3" value="0.1" spread="0.2"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wicoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 7</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 7</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.1"/>
                    <measurement group_id="O4" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.626</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.736</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 14</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 14</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.2"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.220</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 30</title>
        <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BVCA) - Log Score, Day 30</title>
          <description>Best-Corrected Visual Acuity (BCVA) was summarized by the ETDRS visual acuity log score. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis. Treatment comparisons for BCVA were performed by pairwise Wilcoxon tests.</description>
          <population>Subjects with scores at time point.</population>
          <units>Log score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.2"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>WIlcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Baseline</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Baseline</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Baseline</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                    <measurement group_id="O4" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2066</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2066</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5263</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, 2 Hours Post Surgery</title>
        <description>TPostoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, 2 Hours Post Surgery</title>
          <description>TPostoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="2.2" spread="1.3"/>
                    <measurement group_id="O3" value="2.5" spread="1.3"/>
                    <measurement group_id="O4" value="2.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4222</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2712</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8819</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 1</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 1</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="2.3" spread="1.3"/>
                    <measurement group_id="O3" value="2.6" spread="1.3"/>
                    <measurement group_id="O4" value="2.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0510</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8084</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1495</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 2</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 2</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.3"/>
                    <measurement group_id="O2" value="2.0" spread="1.2"/>
                    <measurement group_id="O3" value="2.6" spread="1.4"/>
                    <measurement group_id="O4" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4099</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6499</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0765</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 7</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 7</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.2"/>
                    <measurement group_id="O2" value="1.4" spread="1.2"/>
                    <measurement group_id="O3" value="1.5" spread="1.3"/>
                    <measurement group_id="O4" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0688</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0314</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0775</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 14</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 14</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.7"/>
                    <measurement group_id="O2" value="0.6" spread="0.8"/>
                    <measurement group_id="O3" value="0.7" spread="0.9"/>
                    <measurement group_id="O4" value="0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5369</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3763</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6144</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 30</title>
        <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 30</title>
          <description>Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="0.2" spread="0.5"/>
                    <measurement group_id="O3" value="0.3" spread="0.6"/>
                    <measurement group_id="O4" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1374</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9146</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7599</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on ANOVA model with covariates treatment group and the LOCS II grade group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Baseline</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Baseline</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Baseline</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Two Hours Post-surgery</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Two Hours Post-surgery</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 1</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>One day</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 1</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 2</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 2</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 7</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 7</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.824</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 14</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 14</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.842</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.619</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 30</title>
        <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with scores at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Postoperative Ocular Inflammation SOIS = 0, Day 30</title>
          <description>Number of subjects with Summed Ocular Inflammation Score (SOIS) = 0, summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subjects anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.
Grading was as follows:
Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/&gt;30 cells.
Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous</description>
          <population>Subjects with scores at time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.773</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.592</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.787</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Two Hours Post-Surgery</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>Two hours</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Two Hours Post-Surgery</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="9.4"/>
                    <measurement group_id="O2" value="9.2" spread="11.1"/>
                    <measurement group_id="O3" value="10.9" spread="10.1"/>
                    <measurement group_id="O4" value="10.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.695</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.987</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Day 1</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>One day</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Day 1</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="9.5"/>
                    <measurement group_id="O2" value="9.3" spread="9.7"/>
                    <measurement group_id="O3" value="10.4" spread="8.9"/>
                    <measurement group_id="O4" value="8.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.710</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Day 2</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>Two days</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Day 2</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="6.4"/>
                    <measurement group_id="O2" value="6.8" spread="7.8"/>
                    <measurement group_id="O3" value="10.2" spread="7.6"/>
                    <measurement group_id="O4" value="7.2" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.183</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Day 7</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>Seven days</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Day 7</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="5.2"/>
                    <measurement group_id="O2" value="4.2" spread="7.5"/>
                    <measurement group_id="O3" value="3.6" spread="4.6"/>
                    <measurement group_id="O4" value="6.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Day 14</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>14 days</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Day 14</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.1"/>
                    <measurement group_id="O2" value="1.3" spread="2.4"/>
                    <measurement group_id="O3" value="1.6" spread="2.7"/>
                    <measurement group_id="O4" value="2.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.822</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.424</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.695</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Anterior Chamber Cell Count, Day 30</title>
        <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Anterior Chamber Cell Count, Day 30</title>
          <description>The mean anterior chamber cell count was calculated as the average of the two anterior chamber cell counts. If a cell count was indicated as &gt; 30, it was imputed as 45 for the purpose of treatment comparisons which was performed using pairwise Wilcoxon tests.</description>
          <population>Subjects with data at time point.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.8"/>
                    <measurement group_id="O3" value="0.5" spread="1.2"/>
                    <measurement group_id="O4" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.489</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.459</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.990</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups were based on Wilcoxon rank-sum test. For subjects with mean count &gt; 30, the mean count was imputed as 45 for the purpose of treatment comparisons.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Pain VAS Score After Day 0</title>
        <description>VAS pain scores (where 0 = no pain and 100 = worst possible pain) after the day of surgery were summarized.</description>
        <time_frame>43 days</time_frame>
        <population>Subjects with data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Pain VAS Score After Day 0</title>
          <description>VAS pain scores (where 0 = no pain and 100 = worst possible pain) after the day of surgery were summarized.</description>
          <population>Subjects with data at time point.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 AM; n = 55, 54, 55, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="21.7"/>
                    <measurement group_id="O2" value="13.0" spread="18.1"/>
                    <measurement group_id="O3" value="2.7" spread="8.3"/>
                    <measurement group_id="O4" value="7.7" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 PM; n = 54, 54, 51, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="10.2"/>
                    <measurement group_id="O2" value="12.6" spread="19.4"/>
                    <measurement group_id="O3" value="6.8" spread="15.1"/>
                    <measurement group_id="O4" value="11.6" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 AM; n = 55, 55, 55, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="11.1"/>
                    <measurement group_id="O2" value="10.8" spread="18.2"/>
                    <measurement group_id="O3" value="9.5" spread="18.9"/>
                    <measurement group_id="O4" value="10.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 PM; n = 52, 55, 53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="9.4"/>
                    <measurement group_id="O2" value="7.3" spread="15.5"/>
                    <measurement group_id="O3" value="7.2" spread="15.4"/>
                    <measurement group_id="O4" value="6.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 AM; n = 53, 53, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="7.0"/>
                    <measurement group_id="O2" value="5.4" spread="11.5"/>
                    <measurement group_id="O3" value="4.8" spread="11.3"/>
                    <measurement group_id="O4" value="8.9" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PM; n = 53, 55, 55, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="9.8"/>
                    <measurement group_id="O2" value="5.1" spread="11.0"/>
                    <measurement group_id="O3" value="3.7" spread="8.7"/>
                    <measurement group_id="O4" value="4.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 AM; n = 52, 53, 52, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.0"/>
                    <measurement group_id="O2" value="3.5" spread="8.3"/>
                    <measurement group_id="O3" value="3.9" spread="10.8"/>
                    <measurement group_id="O4" value="5.0" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PM; n = 53, 52, 55, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="9.2"/>
                    <measurement group_id="O2" value="3.7" spread="9.4"/>
                    <measurement group_id="O3" value="4.8" spread="14.2"/>
                    <measurement group_id="O4" value="4.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 AM; n = 54, 54, 53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="9.9"/>
                    <measurement group_id="O2" value="6.4" spread="18.5"/>
                    <measurement group_id="O3" value="3.4" spread="10.6"/>
                    <measurement group_id="O4" value="6.5" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PM; n = 54, 55, 54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="8.5"/>
                    <measurement group_id="O2" value="3.9" spread="10.4"/>
                    <measurement group_id="O3" value="3.3" spread="9.6"/>
                    <measurement group_id="O4" value="5.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 AM; n = 53, 54, 53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="6.3"/>
                    <measurement group_id="O2" value="4.6" spread="13.3"/>
                    <measurement group_id="O3" value="3.6" spread="10.2"/>
                    <measurement group_id="O4" value="6.0" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 PM; n = 54, 53, 54, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="5.5"/>
                    <measurement group_id="O2" value="4.0" spread="11.0"/>
                    <measurement group_id="O3" value="2.7" spread="9.3"/>
                    <measurement group_id="O4" value="4.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7; n = 54, 54, 54, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.3"/>
                    <measurement group_id="O2" value="3.5" spread="9.0"/>
                    <measurement group_id="O3" value="3.3" spread="11.0"/>
                    <measurement group_id="O4" value="4.5" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; n = 22, 28, 21, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.3"/>
                    <measurement group_id="O2" value="4.9" spread="14.7"/>
                    <measurement group_id="O3" value="0.6" spread="1.0"/>
                    <measurement group_id="O4" value="2.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9; n = 4, 4, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10; 1, 2, 3, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11; n = 1, 2, 4, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12; n = 2, 2, 2, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13; n = 11, 8, 15, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                    <measurement group_id="O3" value="0.7" spread="1.8"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n = 17, 16, 21, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.7"/>
                    <measurement group_id="O2" value="0.2" spread="0.5"/>
                    <measurement group_id="O3" value="1.0" spread="2.2"/>
                    <measurement group_id="O4" value="0.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 22, 25, 18, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.6"/>
                    <measurement group_id="O2" value="1.8" spread="8.0"/>
                    <measurement group_id="O3" value="0.2" spread="0.4"/>
                    <measurement group_id="O4" value="4.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16; 1, 7, 2, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17; n = 2, 0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.4"/>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18; n = 0, 0, 1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="0.0" spread="0"/>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19; n = 1, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20; n = 0, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21; n = 1, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; n = 0, 1, 1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="0.0" spread="0"/>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26; n = 0, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 27; n = 9, 9, 6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; n = 11, 12, 14, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.9"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.8" spread="2.2"/>
                    <measurement group_id="O4" value="0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n = 16, 14, 18, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                    <measurement group_id="O3" value="1.6" spread="5.1"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30; n = 15, 13, 6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.8"/>
                    <measurement group_id="O2" value="0.3" spread="0.9"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31; n = 2, 2, 1, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 32; n = 0, 0, 5, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33;n = 0, 0, 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 34; n = 1, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35; n = 1, 0, 1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O3" value="0.0" spread="0"/>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36; n = 1, 1, 1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="50.0" spread="0"/>
                    <measurement group_id="O3" value="0.0" spread="0"/>
                    <measurement group_id="O4" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37; n = 0, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n = 0, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="NA">Subjects not available for assessment at time point</measurement>
                    <measurement group_id="O4" value="NA">Subjects not available for assessment at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Use of Ophthalmic Anti-inflammatory Medications</title>
        <description>Ophthalmic anti-inflammatory medications were identified by reviewing concomitant medications. Subject incidence of ophthalmic anti-inflammatory medication use by post-surgery day was presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>up to 30 days</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Use of Ophthalmic Anti-inflammatory Medications</title>
          <description>Ophthalmic anti-inflammatory medications were identified by reviewing concomitant medications. Subject incidence of ophthalmic anti-inflammatory medication use by post-surgery day was presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>All randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bromfenac sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difluprednate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketorlac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketorolac tromethamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loteprednol etabonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nepafenac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prednisolone acetate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4575</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8318</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8946</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Pain Medications at Day 1</title>
        <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>One day</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Pain Medications at Day 1</title>
          <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>All randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Axotal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diclofenac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naproxen Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paracetamol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tramadol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1570</p_value>
            <p_value_desc>Ocular pain medications will be identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 will be presented. Treatment comparisons will be performed using methodology 1.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0839</p_value>
            <p_value_desc>Ocular pain medications will be identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 will be presented. Treatment comparisons will be performed using methodology 1.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0920</p_value>
            <p_value_desc>Ocular pain medications will be identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 will be presented. Treatment comparisons will be performed using methodology 1.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Pain Medications After Day 1</title>
        <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
        <time_frame>up to 30 days</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Balanced Salt Solution (BSS)</title>
            <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
          </group>
          <group group_id="O2">
            <title>OMS302 Mydriatic Solution (PE)</title>
            <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
          </group>
          <group group_id="O3">
            <title>OMS302 Anti-inflammatory Solution (KE)</title>
            <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
          </group>
          <group group_id="O4">
            <title>OMS302 Solution</title>
            <description>OMS302 Solution
OMS302 Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Pain Medications After Day 1</title>
          <description>Ocular pain medications were identified by reviewing concomitant medications. Subject incidence of ocular pain medication use at day 1 and post day 1 were presented. Treatment comparisons were performed using a Cochran-Mantel- Haenszel (CMH) test adjusting for the stratification factor LOCS II grade.</description>
          <population>All randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Axotal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Celecoxib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diclofenac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naproxen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naproxen Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paracetamol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tramadol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tylox</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>Treatment comparisons between OMS302 and each of the other three groups are based on Cochran-Mantel- Haenszel test adjusting for the LOCS II grade group.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Balanced Salt Solution (BSS)</title>
          <description>Balanced Salt Solution (BSS)
Balanced Salt Solution (BSS)</description>
        </group>
        <group group_id="E2">
          <title>OMS302 Mydriatic Solution (PE)</title>
          <description>OMS302 Mydriatic Solution
OMS302 Mydriatic Solution</description>
        </group>
        <group group_id="E3">
          <title>OMS302 Anti-inflammatory Solution (KE)</title>
          <description>OMS302 Anti-inflammatory Solution
OMS302 Anti-inflammatory Solution</description>
        </group>
        <group group_id="E4">
          <title>OMS302 Solution</title>
          <description>OMS302 Solution
OMS302 Solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agreed not to publish or otherwise to disclose Study data without prior written consent from the sponsor for a period of 24 months following Study completion or until data are published in a combined publication (whichever occurs first). The sponsor can review communications containing results prior to public release and embargo those communications for a period that is no longer than 60 days from the date of receipt of the non-public communication. The sponsor cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Omeros Corporation</organization>
      <phone>(206) 676-5000</phone>
      <email>swhitaker@omeros.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

